<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289713/bin/RJME-62-4-883-fig9.jpg"/> </div> <div class="text-side"> <h1>Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.</h1> <p>Microscopic inflammatory aspects involved in tumor development: (A) The increased number of macrophages present in the tumor mass is observed; (B) The mast cells involved in the tumor mass are identified; (C) B-lymphocytes in low numbers, present in the tumor mass, as an adaptive humoral response; (D) T-lymphocytes involved in intratumoral cellular immunity have been identified. Immunomarking with anti-CD68 antibody: (A) ×100. Immunomarking with anti-tryptase antibody: (B) ×100. Immunomarking with anti-CD20 antibody: (C) ×100. Immunomarking with anti-CD3 antibody: (D) ×200. CD: Cluster of differentiation</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35673808/" target="_blank">35673808</a></p><p>Type: Premalignant/Malignant, Category: Smooth muscle</p>
</div> </div></div></body></html>